Nemaura Medical Management
Management criteria checks 1/4
Nemaura Medical's CEO is Faz Chowdhury, appointed in Jan 2009, has a tenure of 16.33 years. directly owns 40.16% of the company’s shares, worth $1.62K. The average tenure of the management team and the board of directors is 4.3 years and 2.7 years respectively.
Key information
Faz Chowdhury
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 16.3yrs |
| CEO ownership | 40.2% |
| Management average tenure | 4.3yrs |
| Board average tenure | 2.7yrs |
Recent management updates
Recent updates
Nemaura Medical GAAP EPS of -$0.17
Aug 15Nemaura Medical GAAP EPS of -$0.59 misses by $0.12, revenue of $0.51M
Jun 30Nemaura Medical: Opportunity In The Consumer-Centered Continuous Glucose Monitoring Market
Mar 10Nemaura Medical (NASDAQ:NMRD) Has Debt But No Earnings; Should You Worry?
Nov 17
Nemaura Medical: From Believer To Skeptic
Sep 20Nemaura: Wearable Monitoring Patches For Type-2 Diabetics Could Be An Inspired Move
Jul 02How Much Of Nemaura Medical Inc. (NASDAQ:NMRD) Do Insiders Own?
Dec 22
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$11m |
| Sep 30 2023 | n/a | n/a | -US$10m |
| Jun 30 2023 | n/a | n/a | -US$13m |
| Mar 31 2023 | US$339k | US$99k | -US$14m |
| Dec 31 2022 | n/a | n/a | -US$13m |
| Sep 30 2022 | n/a | n/a | -US$15m |
| Jun 30 2022 | n/a | n/a | -US$14m |
| Mar 31 2022 | US$113k | US$109k | -US$14m |
| Dec 31 2021 | n/a | n/a | -US$12m |
| Sep 30 2021 | n/a | n/a | -US$10m |
| Jun 30 2021 | n/a | n/a | -US$9m |
| Mar 31 2021 | US$108k | US$105k | -US$6m |
| Dec 31 2020 | n/a | n/a | -US$5m |
| Sep 30 2020 | n/a | n/a | -US$4m |
| Jun 30 2020 | n/a | n/a | -US$4m |
| Mar 31 2020 | US$104k | US$102k | -US$4m |
| Dec 31 2019 | n/a | n/a | -US$4m |
| Sep 30 2019 | n/a | n/a | -US$5m |
| Jun 30 2019 | n/a | n/a | -US$5m |
| Mar 31 2019 | US$105k | US$104k | -US$4m |
Compensation vs Market: Insufficient data to establish whether Faz's total compensation is reasonable compared to companies of similar size in the US market.
Compensation vs Earnings: Faz's compensation has increased whilst the company is unprofitable.
CEO
Faz Chowdhury (51 yo)
16.3yrs
Tenure
US$338,578
Compensation
Dr. Dewan Fazlul Hoque Chowdhury, also known as Faz, Ph. D, founded Nemaura Pharma Limited and also serves as its Chief Executive Officer and Chairman of the Board since 2005. Dr. Chowdhury has been the Ch...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 16.3yrs | US$338.58k | 40.16% $ 1.6k | |
| Head of U.S. Commercial Operations | 4.3yrs | no data | no data | |
| Head of E.U. Commercial Operations & Marketing | 4.3yrs | no data | no data | |
| Global Head of Digital Programs | 4.1yrs | no data | no data |
4.3yrs
Average Tenure
Experienced Management: NMRD's management team is considered experienced (4.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 16.3yrs | US$338.58k | 40.16% $ 1.6k | |
| Advisor of International Growth Opportunities & Member of Executive Advisory Board | 4.2yrs | no data | no data | |
| Independent Director | 1.3yrs | no data | no data | |
| Director | 1.3yrs | no data | no data |
2.7yrs
Average Tenure
Experienced Board: NMRD's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/07 06:35 |
| End of Day Share Price | 2025/05/02 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Nemaura Medical Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Edward Woo | Ascendiant Capital Markets LLC |
| Constantine Davides | D. Boral Capital LLC. |
| Yi Chen | H.C. Wainwright & Co. |